EP2451472A1 - Préparations d'insuline stables à la chaleur et aux agitations - Google Patents

Préparations d'insuline stables à la chaleur et aux agitations

Info

Publication number
EP2451472A1
EP2451472A1 EP10730441A EP10730441A EP2451472A1 EP 2451472 A1 EP2451472 A1 EP 2451472A1 EP 10730441 A EP10730441 A EP 10730441A EP 10730441 A EP10730441 A EP 10730441A EP 2451472 A1 EP2451472 A1 EP 2451472A1
Authority
EP
European Patent Office
Prior art keywords
arg
asp
insulin
glu
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10730441A
Other languages
German (de)
English (en)
Inventor
Anja Pfenninger
Norbert Tennagels
Christiane Fuerst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of EP2451472A1 publication Critical patent/EP2451472A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the invention relates to a process for the preparation of an aqueous, pharmaceutical formulation containing an insulin, an insulin analog or an insulin derivative, wherein the ready-to-use formulation is obtained directly by dissolving the insulin, the
  • Type II diabetes is not generally deficient in insulin, but in a large number of cases, especially in advanced stages, treatment with insulin may be indicated
  • the replacement of the body's insulin secretion by exogenous, usually subcutaneous administration of insulin generally does not approach the above-described quality of the physiological regulation of blood glucose.
  • derailments of blood glucose go up or down, which can be life threatening in their most severe forms.
  • years of high blood glucose levels without initial symptoms represent a significant health risk.
  • the large-scale DCCT study in the USA The Diabetes Control and Complications Trial Research Group (1993) N. Engl. J. Med. 329, 977-986) clearly demonstrated that chronically elevated blood glucose levels are significantly responsible for the development of late diabetic lesions.
  • Diabetic late damage is microvascular and macrovascular damage, which may manifest as retinopathy, nephropathy, or neuropathy, leading to blindness, kidney failure, and loss of extremities, as well as an increased risk of cardiovascular disease
  • Insulin preparations are achieved. Fast-acting formulations are given at meal times to compensate for the postprandial increase in blood glucose. Slow-acting basal insulins should ensure the basic supply of insulin, especially at night, without leading to hypoglycaemia.
  • Insulin is a 51 amino acid polypeptide distributed among 2 amino acid chains: the 21 amino acid A chain and the 30 amino acid B chain. The chains are linked by 2 disulfide bridges. Insulin preparations have been used for diabetes therapy for many years. Not only naturally occurring insulins are used, but more recently also insulin derivatives and analogues.
  • Insulin analogs are analogues of naturally occurring insulins, viz
  • Human insulin or animal insulins which differ in substitution of at least one naturally occurring amino acid residue with other amino acids and / or addition / removal of at least one amino acid residue from the corresponding otherwise identical naturally occurring insulin. These may also be amino acids that are not naturally occurring.
  • Insulin derivatives are derivatives of naturally occurring insulin or a
  • Insulin analog obtained by chemical modification obtained by chemical modification.
  • the chemical modification can eg in the addition of one or more certain consist of chemical groups to one or more amino acids.
  • insulin derivatives and insulin analogues have a slightly altered effect on human insulin. Insulin analogs with accelerated onset of action are described in EP 0 214 826,
  • EP 0 375 437 and EP 0 678 522 EP 0 124 826 relates inter alia. on substitutions of B27 and B28.
  • EP 0 678 522 describes insulin analogues which have different amino acids in position B29, preferably proline, but not glutamic acid.
  • EP 0 375 437 comprises insulin analogues with lysine or arginine in B28, which may optionally be additionally modified in B3 and / or A21.
  • Protected modifications are modified in the asparagine in B3 and at least one other amino acid in positions A5, A15, A18 or A21.
  • insulin derivatives and insulin analogues have a slightly altered effect on human insulin.
  • insulin analogs are described in which at least one amino acid of positions B1 -B6 is replaced by lysine or arginine. Such insulins have a prolonged action according to WO 92/00321.
  • the insulin analogues described in EP-A 0 368 187 also have a delayed action.
  • the concept of intensified insulin therapy seeks to reduce the health risk by aiming for a stable control of blood sugar levels by early administration of basal insulin.
  • the insulin preparations on the market of naturally occurring insulin for insulin substitution differ in the source of insulin (e.g., beef, pork, human insulin) and the composition with which the profile of action (onset and duration of action) can be affected.
  • Insulins include insulin glargine (Gly (A21) Arg (B31) Arg (B32) human insulin) with a prolonged duration of action. Insulin glargine is injected as an acidic, clear solution and due to its solubility properties it falls in the physiological pH range of the
  • Insulin glargine is injected once daily and is distinguished from other long-acting insulins by its low serum profile and the associated reduction in the risk of nocturnal hypoglycemia (Schubert-Zsilavecz et al., 2: 125-130 (2001)).
  • the specific preparation of insulin glargine, which leads to the prolonged duration of action, is in
  • Liquid insulin preparations have a shelf life of approximately 2 years when stored at 2-8 ° C.
  • the shelf life in use allows storage at up to 25 ° C and is given with 4 weeks, mechanical stress (shaking) is too avoid.
  • mechanical stress shocking
  • patients must be careful to ensure that insulin preparation remains a clear solution, as in exceptional cases precipitation of insulin may occur, in part through the formation of so-called “fibrils", which may result in the risk of insufficient dosage of the medicine.
  • the 2-component insulin preparations of the present invention differ from conventional ones in their heat stability and mechanical shock resistance.
  • the heat and shake stability is based on the storage of insulin as a solid until shortly before administration. It has been shown that solid insulin is more stable to degradation (change of molecular structure) than to dissolved heat stress. Furthermore, dissolved insulin precipitates; this represents a biophysical process which can not take place in the solid state. As a result, with comparable heat stress, more bioavailable insulin is available to an insulin preparation when the dissolution process takes place after the heat stress.
  • Aqueous insulin preparations also show a tendency to precipitate insulin upon mechanical stress (shaking).
  • the amount of bioavailable insulin after shaking stress is thus unknown and represents an impairment of the
  • solvent surfactants
  • the solid insulin dissolution process may be performed on-site by the patient or his or her caregiver, for example in a two-chamber vial or other suitable device.
  • Corresponding attempts to completely dissolve insulins in the appropriate solvents and concentrations for an adequate duration ( ⁇ 10min) have been successful. Essentially, success depends on the appropriate pH of the solvent.
  • Solvents are not or not necessarily different from those already on the market. Heat and mech. Stress-resistant and insulins thus offer the following advantages:
  • the 2-component insulin preparations according to the invention offer the above-mentioned advantages. Patients with no or poor access to suitable refrigerators can thus keep appropriate amounts of insulin in stock; also is the
  • the amount of insulin solution in the case of patiens can also be reduced so that the necessary storage period in use can be reduced to a minimum. This may be the addition of antimicrobial
  • Additives such as m-cresol or other phenols are reduced or even obsolete.
  • the preparations can be used for all known insulins, insulin analogues and
  • Insulin derivatives are produced. These include preparations with desirable basal time /
  • the B chain end consists of an amidated basic amino acid residue such as lysine or
  • Argininamide exists, i. in the amidated basic amino acid residue at the B chain end, the carboxyl group of the terminal amino acid is in its amidated one
  • the N-terminal amino acid residue of the insulin A chain is a lysine or arginine residue
  • the amino acid position A21 is occupied by a glycine residue
  • An object of the invention is therefore a process for the preparation of an aqueous, pharmaceutical formulation containing an insulin, an insulin analog or an insulin derivative, or a pharmacologically tolerable salt thereof, wherein the
  • Solvent mixture is carried out, preferably in which the composition of the suitable solvent mixture is determined by
  • Excipients are prepared which correspond to the final concentration of the excipients of the formulation containing an insulin, an insulin analog or an insulin derivative, and
  • Another object of the invention is a method as described above, wherein the insulin, the insulin analogue or the insulin derivative is present as a crystalline or amorphous solid.
  • An object of the invention is a method as described above, wherein the
  • Insulin is selected from a group containing human insulin, porcine insulin and bovine insulin.
  • the invention further provides a method as described above, wherein the insulin analog is selected from a group comprising Gly (A21), Arg (B31), Arg (B32) -human insulin, Lys (B3), Glu (B29) -human insulin, Asp (B28) human insulin, Lys (B28) Pro (B29) human insulin and Des (B30) human insulin.
  • Another object of the invention is a method according to one or more of claims 1 to 3, wherein the insulin analogue is selected from a group containing an insulin analog of the formula I.
  • insulin analog is selected from a group comprising:
  • Another object of the invention is a method as described above, wherein the insulin analogue is selected from a group containing
  • A1 Arg or Gly A5 Asp, Glu or GIn;
  • B-1 Asp Glu or an amino group
  • BO Asp Glu or a chemical bond
  • a further subject of the invention is a method according to one or more of claims 1 to 3, wherein the insulin derivative is selected from a group containing B29-N-myristoyl des (B30) human insulin, B29-N-palmitoyl des (B30) human insulin , B29-N-myhstoyl human insulin, B29-N-palmitoyl human insulin, B28-N-myristoyl Lys B28 Pro B29 human insulin, B28-N-palmitoyl-Lys B28 Pro B29 human insulin, B30-N-myhstoyl-Thr B29 Lys B3 ° human insulin , B30-N-palmitoyl-Thr B29 Lys B30
  • Another object of the invention is a method as described above, wherein in the formulation a preservative selected from a group containing phenol, m-cresol, chlorocresol, benzyl alcohol, parabens is present.
  • Another object of the invention is a method as described above, wherein in the formulation an isotonizing agent selected from a group containing mannitol, sorbitol, lactose, dextrose, trehalose, sodium chloride, glycerol is present.
  • Another object of the invention is a method as described above, wherein the insulin, the insulin analogue and / or the insulin derivative is present in a concentration of 240-3000 nmol / ml
  • Another object of the invention is a method as described above, wherein in the formulation additionally a glucagon-like peptide-1 (GLP1) or an analog or derivative thereof, or exendin-3 or -4 or an analog or derivative thereof is included , preferably in which an analog of exendin-4 is selected from a group comprising
  • Another object of the invention is a method as described above, wherein an analog of exendin-4 is selected from a group containing the Pro 36 [Asp 28 ] exend in-4 (1 -39),
  • Another object of the invention is a pharmaceutical formulation as described above in which an analog of exendin-4 is selected from a group containing
  • Another object of the invention is a method as described above, wherein in the formulation additionally Arg 34 , Lys 26 (N ⁇ ( ⁇ -glutamyl (N ⁇ -hexadecanoyl))) GLP-1 (7-37) [liraglutide] or a pharmacologically tolerable salt thereof is included.
  • Another object of the invention is a method as described above, wherein in the formulation nor a zinc salt is included.
  • Another object of the invention is the use of a method as described above in the large-scale production of an insulin, insulin analog or insulin derivative.
  • Another object of the invention is a two-part set of containers, in which one of the containers an insulin, an insulin analogue or an insulin derivative as a solid and the other container a solvent mixture of a certain pH with the final concentration of the excipients of a desired formulation of an insulin, a Insulin analogues or an insulin derivative; for heat and shake-stable storage of insulin, the insulin analog or the
  • Insulin derivative for later preparing a ready-to-use formulation by dissolving the solid in the solvent mixture as described above.
  • a further subject of the invention is a two-chamber injection system in which one chamber contains an insulin, an insulin analog or an insulin derivative as solid and the other chamber
  • formulation and “preparation” are used interchangeably.
  • Fig. 1 Hypoglycemic effect of new insulin analogues according to formula I in rats
  • Fig. 2 blood sugar lowering effect of new insulin analogues according to formula I in
  • Fig. 3 Hypoglycemic effect of YKL205 in the dog
  • Fig. 4 Zinc dependence of the hypoglycemic effect of YKL205 in the dog
  • Fig. 5 Hypoglycemic effect of insulin analogues of the invention
  • Fig. 6 Hypoglycemic effect of insulin glargine in rats
  • Example 1 Simplified dissolution of insulins in one step (dissolution test)
  • Composition of the market formulation i. taking into account the concentration of all auxiliaries and additives and the pH.
  • Lantus ® auxiliaries and additives zinc chloride, m-cresol, glycerin, pH 4
  • Insuman ® auxiliaries and additives Nathumhydrogenphosphat, m-cresol, glycerin, pH 7.3
  • Dissolution rate (final volume 1 mL) was less than 10 minutes.
  • Insuman ® required a pH of 7.6 to reach a complete solution with the required final pH of 7.3.
  • the dissolution process for the insulins could be realized within a reasonable time frame ( ⁇ 10 min).
  • additives contribute differently to the thermal stability of the dissolved insulin, e.g. the zinc concentration or the pH (N.R.
  • Containers for 14 days at 60 ° C.
  • sources production
  • containers from the same production batch were stored at 4 ° C. and analyzed together with the stressed samples.
  • Insulin preparations, heat- and shake-stable dosage form in a two-component system Large-scale production of insulin preparations:
  • Single-step resolution is a simplified process with the following advantages: fewer steps with fewer intermediate analyzes (e.g., pH) must be made, i.
  • the production of insulin preparations can be done faster.
  • the manufacture is less complicated, resulting in a simplified training of the employees (less complicated SOPs).
  • fewer containers are to be cleaned, which in turn saves working time and material.
  • Heat stress are more stable than dissolved. Degradation took place to a small extent, but loss by precipitation was eliminated, so that more bioavailable insulin was available with comparable heat stress if the dissolution process took place after the heat stress. Precipitation and degradation induced by vigorous shaking of the solid insulins could not be observed.
  • a presentation in solid form can thus be described as generally more temperature-stable and more robust to shaking and consequently safer.
  • administration of the insulins in solid form offers the additional advantage that accidental freezing by the patient can not lead to complication; Solid insulins are known to be stored in the frozen state.
  • Insulin powders instead of dissolved insulins are treated with suitable solvents (generally aqueous systems containing auxiliary agents and additives such as
  • solvents are offered in a two-component system
  • a two-chamber system is described, for example, in WO2007 / 038773 A1.
  • This increases the tolerable temperature range (both towards lower and higher temperatures).
  • the stability to mechanical stress such as strong vibrations increases. As a result, longer shelf lives, lower storage and transportation costs, and safer drug use are expected.
  • Simplified dissolution in one step ensures applicability by the patient.
  • Examples 4 to 8 serve only to determine the biological, pharmacological and physicochemical properties of insulin analogues according to formula I by firstly providing formulations thereof (example 4) and then carrying out corresponding tests (examples 5 to 8).
  • a solution was prepared of the compounds as follows: The insulin analog according to the invention was dissolved at a target concentration of 240 ⁇ 5 ⁇ M in 1 mM hydrochloric acid with 80 ⁇ g / ml zinc (as zinc chloride). The following compositions were used as solvent medium:
  • freeze-dried material was first about a 30% higher amount than due to the molecular weight and the desired
  • Target concentration of 240 ⁇ 5 ⁇ M the final solution was syringed with a 0.2 ⁇ m filter attachment into a with a septum and a crimp cap
  • Example 5 Evaluation of the hypoglycemic effect of novel insulin analogues in the rat The hypoglycemic effect of selected new insulin analogues is tested in male, normal, normoglycemic Wistar rats. Male rats are injected subcutaneously with a dose of 9 nmol / kg of an insulin analogue. Immediately before injecting the insulin analogue and periodically up to eight hours after the injection, blood samples are taken from the animals and the blood sugar content is determined therein. The experiment clearly shows (see Fig. 1) that the insulin analog used according to the invention significantly delayed
  • Example 6 Evaluation of the hypoglycaemic effect of new insulin analogues in the dog
  • the hypoglycemic effect of selected new insulin analogues is tested in male, healthy, normoglycemic beagle dogs.
  • Male animals are injected subcutaneously with a dose of 6 nmol / kg of an insulin analogue.
  • blood samples are taken from the animals and it determines the blood sugar content.
  • the experiment clearly shows (see Fig. 2) that the insulin analog according to the invention used is a clear one
  • hypoglycemic effect of selected new insulin analogues is tested in male, healthy, normoglycemic beagle dogs.
  • Male animals are injected subcutaneously with a dose of 6 nmol / kg and 12 nmol / kg of an insulin analogue.
  • blood samples are taken from the animals and the blood sugar content is determined therein.
  • Example 8 Evaluation of the hypoglycemic effect in dogs at different zinc concentrations in the formulation
  • FIG. 4 shows the result. Thereafter, the time-response curve of the insulin analog according to the invention by the content of zinc ions in the formulation at the same concentration of insulin influence in such a way that at zero or low zinc content observed a rapid onset and the effect persists over 24 hours, while at higher zinc content low onset of action is observed and the insulin action persists well longer than 24 hours.
  • Example 9 Formulation of the amidated insulin derivatives
  • Example 9 The insulin analog according to the invention was dissolved at a target concentration of 240 ⁇ 5 ⁇ M in 1 mM hydrochloric acid with 80 ⁇ g / ml zinc (as zinc chloride).
  • a target concentration 240 ⁇ 5 ⁇ M in 1 mM hydrochloric acid with 80 ⁇ g / ml zinc (as zinc chloride).
  • the freeze-dried material was first weighed about 30% higher amount than required due to the molecular weight and the desired concentration. Thereafter, the present concentration was determined by means of analytical HPLC and the solution was then filled to the required volume to achieve the target concentration with 5 mM hydrochloric acid with 80 ug / mL zinc. If necessary, the pH was readjusted to 3.5 ⁇ 0.1.
  • the final solution was transferred via syringe with a 0.2 ⁇ m filter attachment to a sterile vial sealed with a septum and crimp cap.
  • no optimization of the formulations e.g. with regard to an addition of isotonic agents, preservatives or buffer substances.
  • Example 10 Evaluation of the hypoglycemic effect of novel insulin analogues in the rat
  • the hypoglycemic effect of selected new insulin analogues is tested in male, healthy, normoglycemic Wistar rats.
  • Male rats are injected subcutaneously with a dose of 9 nmol / kg of an insulin analogue.
  • blood samples are taken from the animals and the blood sugar content is determined therein.
  • the experiment clearly shows (see Fig. 5) that the Insulin analog according to the invention leads to a significantly delayed onset of action and a longer, uniform duration of action.
  • Example 11 Evaluation of the hypoglycemic effect of new insulin analogues in the dog
  • the hypoglycemic effect of selected new insulin analogues is tested in male, healthy, normoglycemic beagle dogs.
  • Male animals are injected subcutaneously with a dose of 6 nmol / kg of an insulin analogue.
  • blood samples are taken from the animals and the blood sugar content is determined therein.
  • the experiment clearly shows that the insulin analog according to the invention leads to a markedly delayed, shallow onset of action and a longer, uniform duration of action.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un procédé pour produire une formulation pharmaceutique aqueuse contenant de l'insuline, un analogue à l'insuline ou un dérivé d'insuline, la formulation prête à l'utilisation pouvant être obtenue directement par dissolution de l'insuline, de l'analogue à l'insuline ou du dérivé d'insuline en tant que matière solide avec un mélange de solvants approprié.
EP10730441A 2009-07-06 2010-07-02 Préparations d'insuline stables à la chaleur et aux agitations Withdrawn EP2451472A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009031754 2009-07-06
US26435809P 2009-11-25 2009-11-25
PCT/EP2010/059430 WO2011003820A1 (fr) 2009-07-06 2010-07-02 Préparations d'insuline stables à la chaleur et aux agitations

Publications (1)

Publication Number Publication Date
EP2451472A1 true EP2451472A1 (fr) 2012-05-16

Family

ID=43428814

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10730441A Withdrawn EP2451472A1 (fr) 2009-07-06 2010-07-02 Préparations d'insuline stables à la chaleur et aux agitations

Country Status (7)

Country Link
US (1) US20120241356A1 (fr)
EP (1) EP2451472A1 (fr)
JP (1) JP2012532177A (fr)
AR (1) AR077453A1 (fr)
TW (1) TW201105346A (fr)
UY (1) UY32761A (fr)
WO (1) WO2011003820A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ586590A (en) 2008-01-09 2012-06-29 Sanofi Aventis Deutschland Insulin analogues or derivatives having an extremely delayed time-action profile
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
WO2011003823A1 (fr) * 2009-07-06 2011-01-13 Sanofi-Aventis Deutschland Gmbh Préparations d'insuline à effet retard
ES2965209T3 (es) 2009-11-13 2024-04-11 Sanofi Aventis Deutschland Composición farmacéutica que comprende desPro36exendina-4(1-39)-Lys6-NH2 y metionina
EP3831402A1 (fr) 2009-11-13 2021-06-09 Sanofi-Aventis Deutschland GmbH Composition pharmaceutique comprenant un agoniste du glp-1, une insuline et de la méthionine
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
JP6584953B2 (ja) 2012-11-05 2019-10-02 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 長時間作用型単鎖インスリン類似体
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
MX2016008978A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
CA2932873A1 (fr) 2014-01-09 2015-07-16 Sanofi Formulations pharmaceutiques stabilisees d'insuline asparte
MX2016008979A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
DK3229828T5 (da) 2014-12-12 2024-10-14 Sanofi Aventis Deutschland Formulering med fast forhold mellem insulin glargin og lixisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
EP3668892A1 (fr) 2017-08-17 2020-06-24 Novo Nordisk A/S Nouveaux analogues d'insuline acylés et leurs utilisations

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2161198A (en) * 1937-02-01 1939-06-06 Burroughs Wellcome Co Insulin preparation
GB1106076A (en) 1964-05-26 1968-03-13 Wellcome Found Stable, aqueous insulin solutions
DE2023447A1 (de) * 1970-05-08 1971-11-25 National Research Development Corp., London Insulinderivate und Verfahren zu ihrer Herstellung
DE3316363A1 (de) 1983-05-05 1984-11-08 Deutsche Babcock Anlagen Ag, 4200 Oberhausen Walzenrost fuer muellverbrennungsanlagen
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
DK113585D0 (da) * 1985-03-12 1985-03-12 Novo Industri As Nye peptider
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5225323A (en) * 1988-11-21 1993-07-06 Baylor College Of Medicine Human high-affinity neurotransmitter uptake system
KR910700262A (ko) * 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
PT93057B (pt) * 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
DK155690D0 (da) * 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
CN1188171C (zh) * 1994-06-02 2005-02-09 廓德伦特控股剑桥有限公司 防止各种特质在再水化或熔化时聚集的方法以及由此获得的组合物
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
KR20010024556A (ko) * 1997-10-24 2001-03-26 피터 지. 스트링거 불용성 인슐린 조성물
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CN1160122C (zh) * 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
WO2004096266A1 (fr) 2003-05-02 2004-11-11 Novo Nordisk A/S Stabilite physique amelioree de preparations d'insuline
US20070010423A1 (en) * 2003-06-27 2007-01-11 Karsten Wassermann Compositions comprising balaglitazone and further antidiabetic compounds
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
CA2580313C (fr) * 2004-07-19 2016-03-15 Biocon Limited Conjugues insuline-oligomere, preparations et utilisations de ceux-ci
WO2007038773A1 (fr) 2005-09-28 2007-04-05 Biodel, Inc. Dispositif pour preparation injectable a deux chambres autoremplissables
US8343914B2 (en) * 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
NZ586590A (en) * 2008-01-09 2012-06-29 Sanofi Aventis Deutschland Insulin analogues or derivatives having an extremely delayed time-action profile
CN102186521B (zh) * 2008-09-18 2013-07-24 贝克顿·迪金森公司 具有用于自动重构的剂量旋钮致动机构的医用注射器
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2011003820A1 *

Also Published As

Publication number Publication date
JP2012532177A (ja) 2012-12-13
AR077453A1 (es) 2011-08-31
TW201105346A (en) 2011-02-16
WO2011003820A1 (fr) 2011-01-13
UY32761A (es) 2011-01-31
US20120241356A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
WO2011003820A1 (fr) Préparations d'insuline stables à la chaleur et aux agitations
EP2451437B1 (fr) Préparations aqueuses de l'insuline contenant de la méthionine
EP2349324B1 (fr) Combinaison d'une insuline et d'un agoniste de glp-1
EP3417871B1 (fr) Composition pharmaceutique comprenant un agoniste glp-1, de l'insuline et de la methionine
EP2498801B1 (fr) COMPOSITION PHARMACEUTIQUE COMPRENANT desPro36Exendin-4(1-39)-Lys6-NH2 ET DE LA MÉTHIONINE
EP2305288B1 (fr) Préparations d'insuline amères dotées d'une stabilité améliorée
EP2451471A1 (fr) Préparations d'insuline à effet retard
EP2289539B1 (fr) Préparations d'insuline sans zinc ou pauvre en zinc dotées d'une stabilité améliorée
DE60033437T2 (de) Glp-2 enthaltende formulierungen
DE102008053048A1 (de) Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008003568A1 (de) Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE69806362T2 (de) Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält
EP1806361B1 (fr) Formulation liquide d'erythropoietine
DE102008025008A1 (de) Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008051834A1 (de) Kombination von einem Insulin und einem GLP-1-Agonisten
DE102009038210A1 (de) Kombination von einem Insulin und einem GLP-1-Agonisten
DE102010011919A1 (de) Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20170120

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20170529